The basal cell nevus syndrome market is expected to witness steady growth driven by increasing awareness, advances in targeted therapies, and the development of novel hedgehog pathway inhibitors.
Please provide your email address to receive an email when new articles are posted on . Five-year recurrence-free survival was 55.1% with nevus-associated acral melanoma (NAAM) vs. 42.3% with de novo ...
The basal cell nevus syndrome market is expected to witness steady growth driven by increasing awareness, advances in targeted therapies, and the development of novel hedgehog ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback